Ranbaxy Laboratories on July 28 said it has launched the generic version of Omeprazole capsules, used in the treatment of acid related diseases in the US healthcare system. Ranbaxy Pharmaceuticals Inc (RPI), the wholly-owned subsidiary of Ranbaxy Laboratories under an agreement with AstraZeneca Pharmaceuticals has launched an authorised generic of Omeprazole 40 mg capsules in the US.
RPI welcome the opportunity to market an authorized generic of Omeprazole 40 mg capsules that will be commercialised immediately to all classes of trade in the US healthcare system under Ranbaxy lebel. RPI is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.
RPI welcome the opportunity to market an authorized generic of Omeprazole 40 mg capsules that will be commercialised immediately to all classes of trade in the US healthcare system under Ranbaxy lebel. RPI is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.
No comments:
Post a Comment